← ARROWHEAD PHARMACEUTICALS, INC. ARWR
Market Price
$86.67
Market Cap
$12.06B
P/E Ratio
N/A
Revenue (FY 2025)
↑23,258.2% YoY
$829.45M
3-Yr CAGR: 50.5%
Net Income
↑99.7% YoY
-$1.63M
Net Margin: -0.2%
Free Cash Flow
↑126.0% YoY
$156.89M
FCF Yield: 1.30%
EPS (Diluted)
↑99.8% YoY
$-0.01
Basic: $-0.01
Return on Equity
Efficiency
-0.3%
ROA: -0.2%
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (ARWR)
All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
- FY 2017: Revenue YoY (+19736.5%) is identical to Gross Profit YoY (+19736.5%). Verify the underlying Revenue and Gross Profit values for FY 2017 and FY 2016.
- FY 2018: Revenue YoY (-48.6%) is identical to Gross Profit YoY (-48.6%). Verify the underlying Revenue and Gross Profit values for FY 2018 and FY 2017.
- FY 2021: Revenue YoY (+57.2%) is identical to Gross Profit YoY (+57.2%). Verify the underlying Revenue and Gross Profit values for FY 2021 and FY 2020.
- FY 2022: Revenue YoY (+75.9%) is identical to Gross Profit YoY (+75.9%). Verify the underlying Revenue and Gross Profit values for FY 2022 and FY 2021.
| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2016 | $0.2M | — | $0.2M | $-81.7M | — | $-1.34 | — | $-64.4M | $-68.3M | — |
| FY 2017 | $31.4M | +19,736.5% | $31.4M | — | — | $-0.47 | +64.9% | $-23.9M | $-31.9M | +53.3% |
| FY 2018 | $16.1M | -48.6% | $16.1M | — | — | $-0.65 | -38.3% | $-47.2M | $-48.6M | -52.7% |
| FY 2019 | $168.8M | +945.7% | $87.7M | $68.0M | — | $0.69 | +206.2% | $173.0M | $161.0M | +431.0% |
| FY 2020 | $88.0M | -47.9% | $88.0M | $-84.6M | -224.4% | $-0.84 | -221.7% | $-95.4M | $-107.3M | -166.7% |
| FY 2021 | $138.3M | +57.2% | $138.3M | $-140.8M | -66.6% | $-1.36 | -61.9% | $171.2M | $147.7M | +237.6% |
| FY 2022 | $243.2M | +75.9% | $243.2M | $-176.1M | -25.0% | $-1.67 | -22.8% | $-136.1M | $-188.9M | -227.9% |
| FY 2023 | $240.7M | -1.0% | $222.4M | $-205.3M | -16.6% | $-1.92 | -15.0% | $-153.9M | $-330.6M | -75.0% |
| FY 2024 | $3.6M | -98.5% | $3.6M | $-599.5M | -192.0% | $-5.00 | -160.4% | $-462.9M | $-604.3M | -82.8% |
| FY 2025 | $829.4M | +23,258.2% | $740.1M | $-1.6M | +99.7% | $-0.01 | +99.8% | $179.6M | $156.9M | +126.0% |
Valuation
Market Price
$86.67
Market Cap
$12.06B
Enterprise Value
N/A
P/E Ratio
N/A
P/B Ratio
26.19
FCF Yield
1.30%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
89.23%
Operating Margin
11.86%
Net Margin
-0.20%
Return on Equity (ROE)
-0.35%
Return on Assets (ROA)
-0.17%
Asset Turnover
0.87x
Revenue 3-Yr CAGR
50.52%
Financial Health & Liquidity
Current Ratio
10.51
Cash Ratio
2.04
Debt / Equity
N/A
Debt / Assets
N/A
Cash & Equivalents
$184.43M
Total Debt
N/A
Book Value / Share
$3.31
Cash Flow Efficiency
Operating Cash Flow
$179.55M
Capital Expenditures (CapEx)
$22.67M
Free Cash Flow
$156.89M
OCF / Revenue
21.65%
FCF / Revenue
18.91%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
$-0.01
EPS (Basic)
$-0.01
Dividends / Share
N/A
Book Value / Share
$3.31
EPS YoY Growth
99.80%
Balance Sheet (FY 2025)
Total Assets
$950.64M
Total Liabilities
$90.42M
Stockholders' Equity
$466.05M
Current Assets
$950.64M
Current Liabilities
$90.42M